DGUOK Antibody

Code CSB-PA621974HA01HU
Size US$166
Order now
Image
  • Immunohistochemistry of paraffin-embedded human liver cancer using CSB-PA621974HA01HU at dilution of 1:100

  • Immunohistochemistry of paraffin-embedded human skeletal muscle tissue using CSB-PA621974HA01HU at dilution of 1:100

The Latest Promotion Free Antibody trial simple
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Full Product Name
Rabbit anti-Homo sapiens (Human) DGUOK Polyclonal antibody
Uniprot No.
Target Names
DGUOK
Alternative Names
DGUOK antibody; DGK antibody; Deoxyguanosine kinase antibody; mitochondrial antibody; dGK antibody; EC 2.7.1.113 antibody
Raised in
Rabbit
Species Reactivity
Human
Immunogen
Recombinant Human Deoxyguanosine kinase, mitochondrial protein (40-277AA)
Immunogen Species
Homo sapiens (Human)
Conjugate
Non-conjugated

The DGUOK Antibody (Product code: CSB-PA621974HA01HU) is Non-conjugated. For DGUOK Antibody with conjugates, please check the following table.

Available Conjugates
Conjugate Product Code Product Name Application
HRP CSB-PA621974HB01HU DGUOK Antibody, HRP conjugated ELISA
FITC CSB-PA621974HC01HU DGUOK Antibody, FITC conjugated
Biotin CSB-PA621974HD01HU DGUOK Antibody, Biotin conjugated ELISA
Clonality
Polyclonal
Isotype
IgG
Purification Method
>95%, Protein G purified
Concentration
It differs from different batches. Please contact us to confirm it.
Buffer
Preservative: 0.03% Proclin 300
Constituents: 50% Glycerol, 0.01M PBS, PH 7.4
Form
Liquid
Tested Applications
ELISA, IHC
Recommended Dilution
Application Recommended Dilution
IHC 1:20-1:200
Troubleshooting and FAQs
Storage
Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
Lead Time
Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.

Customer Reviews and Q&A

 Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Target Background

Function
Phosphorylates deoxyguanosine and deoxyadenosine in the mitochondrial matrix, with the highest efficiency for deoxyguanosine. In non-replicating cells, where cytosolic dNTP synthesis is down-regulated, mtDNA synthesis depends solely on DGUOK and TK2. Phosphorylates certain nucleoside analogs. Widely used as target of antiviral and chemotherapeutic agents.
Gene References into Functions
  1. DGUOK deficiency and mutation is associated with mitochondrial DNA depletion syndromes. PMID: 28493820
  2. rare homozygous p.N46S mutation associated with idiopathic noncirrhotic portal hypertension PMID: 26874653
  3. The goals of this work are to characterize the DGUOK rat in terms of mitochondrial dysfunction and pathological outcome, and to evaluate EPR as a new and additional technique in an integrated characterization of mitochondrial disease . PMID: 26773591
  4. sequencing results showed that the patient was a compound heterozygote for c.679G>A and c.817delT in the DGUOK gene PMID: 27324545
  5. thymidine kinase 2 but not deoxyguanosine kinase is up-regulated during the stationary growth phase of cultured cells PMID: 24940680
  6. study expands the spectrum of disorders caused by mutations in DGUOK. PMID: 23043144
  7. Deoxyguanosine kinase gene mutations combined with impaired glucose homeostasis and iron overload features are associated with severe progressive liver failure. PMID: 21107780
  8. c.592-4_c.592-3delTT mutation causes exon skipping and is and responsible for the DGUOK deficiency PMID: 19900589
  9. Neurological symptoms appeared later and were mild, in agreement with the limited brain pathology. Molecular analysis of the dGK gene should be performed in infants with cirrhosis even in the absence of CNS involvement. PMID: 15150663
  10. Low level of mitochondrial deoxyguanosine kinase is the dominant factor in acquired resistance to 9-beta-D-arabinofuranosylguanine cytotoxicity PMID: 12054684
  11. A novel mutation in the deoxyguanosine kinase gene causing depletion of mitochondrial DNA. Homozygous nonsense mutation in exon 3 of DGUOK (313C-->T). PMID: 12210798
  12. This study identified 2 novel homozygous mutations, G352A and C269T, that lead to truncated proteins in the hepatocerebral form of mitochondrial DNA depletion syndrome. PMID: 15883261
  13. DGUOK activity may play a crucial role in the phenotype reversal PMID: 17073823
  14. DGUOK is required for mitochondrial DNA replication in resting cells and that small changes in expression of this enzyme may cause mitochondrial DNA depletion. PMID: 17490647
  15. 15 different mutations in the DGUOK gene from 9 kindreds, were identified. PMID: 18205204
  16. study reports the first founder DGUOK mutation (c.444-62C>A) in two North-African families with hepatocerebral syndrome and severe combined respiratory chain deficiency PMID: 19394258
  17. a viral infection can trigger fulminant liver failure in the context of a genetic predisposition associated with mutations in DGUOK PMID: 19502998

Show More

Hide All

Involvement in disease
Mitochondrial DNA depletion syndrome 3 (MTDPS3); Portal hypertension, non-cirrhotic (NCPH); Progressive external ophthalmoplegia with mitochondrial DNA deletions, autosomal recessive 4 (PEOB4)
Subcellular Location
Mitochondrion.
Protein Families
DCK/DGK family
Tissue Specificity
Ubiquitous. Highest expression in muscle, brain, liver and lymphoid tissues.
Database Links

HGNC: 2858

OMIM: 251880

KEGG: hsa:1716

STRING: 9606.ENSP00000264093

UniGene: Hs.469022

icon of phone
Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
icon of address
Address
7505 Fannin St., Ste 610, Room 7 (CUBIO Innovation Center), Houston, TX 77054, USA
icon of social media
Join us with

Subscribe newsletter

Leave a message

* To protect against spam, please pass the CAPTCHA test below.
CAPTCHA verification
© 2007-2024 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1
Place an order now

I. Product details

*
*
*
*

II. Contact details

*
*

III. Ship To

*
*
*
*
*
*
*

IV. Bill To

*
*
*
*
*
*
*
*